ProCE Banner Activity

ASCEMBL: 96-Wk Update of Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2 TKIs

Slideset Download
Conference Coverage
At a median follow-up of 2.3 years, asciminib continues to show deeper and more durable responses with more favorable safety compared with bosutinib among patients with CML-CP previously treated with ≥2 TKIs.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab